Best Peptides for Cognitive Enhancement

Evidence level: Peer reviewed (100+ clinical trials, Cochrane review; mixed results)

Regulatory status: Approved in 40+ countries (primarily Europe and Asia); not FDA-approved for use in the United States

Cerebrolysin is a porcine brain-derived peptide preparation with proposed neurotrophic and neuroprotective activity, approved and marketed in over 40 countries for neurological indications including stroke and dementia. A Cochrane systematic review (Cui et al., 2019) examined its use in vascular dementia, finding it is administered as daily intravenous infusions in many countries but concluding that results were inconsistent and higher-quality trials are needed. A 2025 prospective, randomized, open-label, blinded-endpoint pilot trial (CLINCH) evaluated Cerebrolysin for intracerebral hemorrhage, finding it was safe and feasible to study. A 2026 systematic review and meta-analysis found that Cerebrolysin as an adjunct to mechanical thrombectomy in acute ischemic stroke showed promise but required further study. While the volume of clinical data is substantial, the Cochrane review specifically noted inconsistency in results and a need for higher-quality trials. Cerebrolysin is not approved by the FDA for any indication and is not legally available in the United States.

Evidence level: Peer reviewed (Russian clinical trials — small, no Western replication)

Regulatory status: Registered as a pharmaceutical in Russia for mild cognitive impairment; sold as an unregulated dietary supplement in the US — not FDA-approved

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a dipeptide nootropic compound developed in Russia and registered there as a pharmaceutical for mild cognitive impairment. It is structurally related to piracetam but considerably more potent on a per-milligram basis in animal models. Two Russian clinical trials have been published: a 2011 study in stroke patients with mild cognitive impairment (PMID 22500312) and a 2008 EEG-characterized study of MCI patients of post-traumatic and vascular origin (PMID 19008801), both in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. These are small studies (dozens of patients), predominantly Russian-language, and have not been independently replicated in Western populations. Preclinical mechanism studies include a 2022 Neuroscience Letters study demonstrating alpha7 nicotinic acetylcholine receptor involvement on hippocampal interneurons in rats (PMID 36195298) and a 2020 study showing Noopept activates the transcription factor HIF-1 (PMID 33119829). A 2025 physicochemical analysis confirmed its structural identity. In the United States, Noopept is sold as a dietary supplement without FDA drug approval. Russian clinical trials should not be extrapolated to general cognitive enhancement in healthy individuals.

Evidence level: Peer reviewed (Russian-language clinical publications — no Western replication)

Regulatory status: Registered as a medicine in Russia; not FDA-approved — investigational, listed for FDA advisory committee discussion

Semax is a heptapeptide analog of ACTH registered as a medicine in Russia for cognitive and attention-related indications. Russian-language clinical and preclinical publications describe cognitive and attention-enhancing effects, but these studies are primarily from Russian institutions and have not been replicated in Western clinical trials. A connectomic study (Myagkov et al., 2020) examined brain functional connectivity changes from Semax and the related peptide Selank in rats. Semax is not FDA-approved for any indication and is scheduled for discussion at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting. It appears on the FDA bulk drug substances risk list for compounded products. Biohacking communities discuss Semax as a cognitive enhancer despite its lack of FDA approval or regulatory recognition outside Russia. The clinical evidence is limited to Russian-language publications without independent Western replication.

Evidence level: Preclinical only (animal models) — no published human clinical trials

Regulatory status: Not FDA-approved for any indication — investigational, preclinical only; sold as research chemical

Dihexa (N-hexanoic-tyr-ile-(6) aminohexanoic amide) is a metabolically stabilized analog of angiotensin IV developed at Washington State University by Harding, Wright, and colleagues. It was designed to activate the hepatocyte growth factor (HGF)/c-Met receptor system, which is implicated in synaptogenesis and cognitive function. The key pharmacological characterization was published in JPET in 2013 (PMID 23055539). A 2014 JPET study established that Dihexa's procognitive and synaptogenic effects depend on HGF/c-Met activation (PMID 25455861). A 2021 Brain Sciences study demonstrated cognitive rescue in APP/PS1 transgenic Alzheimer's mouse models via the PI3K/AKT pathway (PMID 34827486), and a 2024 Journal of Huntington's Disease study showed effects in a 3-nitropropionic acid rat model of Huntington's disease (PMID 38489193). A 2015 review by Wright et al. in Progress in Neurobiology describes the development of angiotensin IV analogs for neurodegenerative disease. However, no human clinical trials have been published. The widely-repeated claim that Dihexa is '10 million times stronger than BDNF' is a sensationalized extrapolation from a single 2013 rat study comparing relative potency in an in vitro dendritic spine assay — not clinical efficacy. Dihexa is not FDA-approved for any indication and is sold as a 'research chemical' or supplement despite lacking any clinical safety or efficacy data in humans.